Patents by Inventor Matthew H. Daniels

Matthew H. Daniels has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BIOMARKER-BASED TREATMENT OF FOCAL SEGMENTAL GLOMERULOSCLEROSIS AND DIABETIC KIDNEY DISEASE
    Publication number: 20240091303
    Abstract: Disclosed are compounds having structural formulas (I)-(XI), and related pharmaceutical compositions. Also disclosed are methods of selecting and treating human subjects suffering from a kidney disease, using the compounds of formulas (I)-(XI), and methods of determining the efficacy of TRPC5 inhibitor therapies using the same.
    Type: Application
    Filed: October 5, 2020
    Publication date: March 21, 2024
    Inventors: John Francis Reilly, Yossi Dagon, Hari Raghu, Marie-Francoise Yveline Coeffet-Le Gal, Matthew H. Daniels, Maolin Yu, Mark W. Ledeboer, Jean-Christophe P. Harmange, Peter H. Mundel
  • METTL3 MODULATORS
    Publication number: 20240051985
    Abstract: Provided are compounds of Formula (I?) or (I) below, or pharmaceutically acceptable salts thereof, and methods for their use and production.
    Type: Application
    Filed: October 13, 2021
    Publication date: February 15, 2024
    Inventors: Matthew H. Daniels, Thomas Andrew Wynn, Brian Andrew Sparling, Ernest Allen Sickmier, Andrew Stewart Tasker, James Edward John Mills
  • IMIDAZODIAZEPINEDIONES AND METHODS OF USE THEREOF
    Publication number: 20230365575
    Abstract: Disclosed are compounds according to Formula (I) or (II), and pharmaceutical compositions comprising them. Also disclosed are therapeutic methods, e.g., of treating kidney diseases, using the compounds of Formula (I) or (II).
    Type: Application
    Filed: February 1, 2023
    Publication date: November 16, 2023
    Inventors: Matthew H. Daniels, Maolin Yu, Jean-Christophe P. Harmange, Thomas T. Tibbitts, Mark W. Ledeboer, Neil A. Castle, Goran Malojcic
  • PYRIDAZINONES AND METHODS OF USE THEREOF
    Publication number: 20230203028
    Abstract: Disclosed are compounds according to Formula (A), and related tautomers and pharmaceutical compositions. Also disclosed are therapeutic methods, e.g., of treating kidney diseases, using the compounds of Formula (A).
    Type: Application
    Filed: September 18, 2018
    Publication date: June 29, 2023
    Inventors: Maolin Yu, Matthew H. Daniels, Jean-Christophe P. Harmange, Thomas T. Tibbitts, Mark W. Ledeboer, Goran Malojcic, Liron Walsh, Peter H. Mundel
  • Imidazodiazepinediones and methods of use thereof
    Patent number: 11623930
    Abstract: Disclosed are compounds according to Formula (I) or (II), and pharmaceutical compositions comprising them. Also disclosed are therapeutic methods, e.g., of treating kidney diseases, using the compounds of Formula (I) or (II).
    Type: Grant
    Filed: March 5, 2019
    Date of Patent: April 11, 2023
    Assignee: Goldfinch Bio, Inc.
    Inventors: Matthew H. Daniels, Maolin Yu, Jean-Christophe P. Harmange, Thomas T. Tibbitts, Mark W. Ledeboer, Neil A. Castle, Goran Malojcic
  • METTL3 MODULATORS
    Publication number: 20230027361
    Abstract: Provided are compounds of Formula (I?) or (II?), or pharmaceutically acceptable salts thereof, and methods for their use and production.
    Type: Application
    Filed: October 20, 2020
    Publication date: January 26, 2023
    Applicant: Accent Therapeutics, Inc.
    Inventors: Thomas Andrew Wynn, Brian Lewis Hodous, Paula Ann Boriack-Sjodin, Ernest Allen Sickmier, James Edward John Mills, Robert A. Copeland, Andrew Stewart Tasker, Matthew H. Daniels, Kenneth W. Duncan, Brian Andrew Sparling
  • SUBSTITUTED 1,6-NAPHTHYRIDINE INHIBITORS OF CDK5
    Publication number: 20220389009
    Abstract: Disclosed are compounds having structural formula I, and related salts and pharmaceutical compositions. Also disclosed are therapeutic methods, e.g., of treating diseases and conditions such as kidney disease, kidney failure, kidney stones, or polycystic kidney disease, using the compounds of formula (I), and related salts and pharmaceutical compositions.
    Type: Application
    Filed: October 1, 2020
    Publication date: December 8, 2022
    Inventors: Goran Malojcic, Matthew H. Daniels, Brett D. Williams, Maolin Yu, Mark W. Ledeboer, Jean-Christophe P. Harmange, Jenna L. Wang
  • PYRIDAZINONES AND METHODS OF USE THEREOF
    Publication number: 20220152031
    Abstract: Disclosed are therapeutic methods, e.g., of treating kidney diseases, using compounds of Formula (A) in combination with a second therapeutic agent.
    Type: Application
    Filed: March 18, 2020
    Publication date: May 19, 2022
    Inventors: John Francis Reilly, Liron Walsh, Peter H. Mundel, Amy Kieu Duyen Westerling-Bui, Matthew H. Daniels, Maolin Yu, Mark W. Ledeboer, Jean-Christophe P. Harmange, Marie-Francoise Yveline Coeffet-Le Gal, Michael Broxson
  • PYRIDAZINONES AND METHODS OF USE THEREOF
    Publication number: 20220024917
    Abstract: Disclosed are compounds according to Formula (I), and related pharmaceutical compositions. Also disclosed are therapeutic methods, e.g., of treating kidney diseases, using the compounds of Formula (I).
    Type: Application
    Filed: June 28, 2021
    Publication date: January 27, 2022
    Inventors: Mark W. Ledeboer, Matthew H. Daniels, Maolin Yu, Jean-Christophe P. Harmange
  • Pyridazinones and methods of use thereof
    Patent number: 11046690
    Abstract: Disclosed are compounds according to Formula (I), and related pharmaceutical compositions. Also disclosed are therapeutic methods, e.g., of treating kidney diseases, using the compounds of Formula (I).
    Type: Grant
    Filed: May 18, 2020
    Date of Patent: June 29, 2021
    Assignee: Goldfinch Bio, Inc.
    Inventors: Mark W. Ledeboer, Matthew H. Daniels, Maolin Yu, Jean-Christophe P. Harmange
  • IMIDAZODIAZEPINEDIONES AND METHODS OF USE THEREOF
    Publication number: 20210087200
    Abstract: Disclosed are compounds according to Formula (I) or (II), and pharmaceutical compositions comprising them. Also disclosed are therapeutic methods, e.g., of treating kidney diseases, using the compounds of Formula (I) or (II).
    Type: Application
    Filed: March 5, 2019
    Publication date: March 25, 2021
    Inventors: Matthew H. Daniels, Maolin Yu, Jean-Christophe P. Harmange, Thomas T. Tibbitts, Mark W. Ledeboer, Neil A. Castle, Goran Malojcic
  • BENZIMIDAZOLES AND AZA-BENZIMIDAZOLES, AND METHODS OF USE THEREOF
    Publication number: 20200377505
    Abstract: Disclosed are compounds according to Formula (I) or (II), and pharmaceutical compositions comprising them. Also disclosed are therapeutic methods, e.g., of treating kidney diseases, using the compounds of Formula (I) or (II).
    Type: Application
    Filed: August 3, 2018
    Publication date: December 3, 2020
    Inventors: Mark W. Ledeboer, Jean-Christophe P. Harmange, Maolin Yu, Thomas T. Tibbitts, Matthew H. Daniels
  • PYRIDAZINONES AND METHODS OF USE THEREOF
    Publication number: 20200283437
    Abstract: Disclosed are compounds according to Formula (I), and related pharmaceutical compositions. Also disclosed are therapeutic methods, e.g., of treating kidney diseases, using the compounds of Formula (I).
    Type: Application
    Filed: May 18, 2020
    Publication date: September 10, 2020
    Inventors: Mark W. Ledeboer, Matthew H. Daniels, Maolin Yu, Jean-Christophe P. Harmange
  • Pyridazinones and methods of use thereof
    Patent number: 10654850
    Abstract: Disclosed are compounds according to Formula (I), and related pharmaceutical compositions. Also disclosed are therapeutic methods, e.g., of treating kidney diseases, using the compounds of Formula (I).
    Type: Grant
    Filed: September 18, 2019
    Date of Patent: May 19, 2020
    Assignee: Goldfinch Bio, Inc.
    Inventors: Mark W. Ledeboer, Matthew H. Daniels, Maolin Yu, Jean-Christophe P. Harmange
  • PYRIDAZINONES AND METHODS OF USE THEREOF
    Publication number: 20200102301
    Abstract: Disclosed are compounds according to Formula (I), and related pharmaceutical compositions. Also disclosed are therapeutic methods, e.g., of treating kidney diseases, using the compounds of Formula (I).
    Type: Application
    Filed: September 18, 2019
    Publication date: April 2, 2020
    Inventors: Mark W. Ledeboer, Matthew H. Daniels, Maolin Yu, Jean-Christophe P. Harmange
  • Compounds that are ERK inhibitors
    Patent number: 9233979
    Abstract: Disclosed are the ERK inhibitors of formula (1): and the pharmaceutically acceptable salts thereof. Also disclosed are methods of treating cancer using the compounds of formula (1).
    Type: Grant
    Filed: September 26, 2013
    Date of Patent: January 12, 2016
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Kevin J. Wilson, David J. Witter, Phieng Siliphaivanh, Kathryn Lipford, David Sloman, Danielle Falcone, Brendan O'Boyle, Umar Faruk Mansoor, Jongwon Lim, Joey L. Methot, Christopher Boyce, Lei Chen, Matthew H. Daniels, Salem Fevrier, Xianhai Huang, Ravi Kurukulasuriya, Ling Tong, Wei Zhou, Joseph Kozlowski, Milana M. Maletic, Bidhan A. Shinkre, Jayanth Thiruvellore Thatai, Raman Kumar Bakshi, Ganesh Babu Karunakaran
  • Compounds that are ERK inhibitors
    Patent number: 9226922
    Abstract: Disclosed are the ERK inhibitors of formula (1.0), having a pyrazolopyridine base structure, and the pharmaceutically acceptable salts thereof. Also disclosed are methods of treating cancer using the compounds of formula (1.0).
    Type: Grant
    Filed: September 26, 2013
    Date of Patent: January 5, 2016
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Kevin J. Wilson, David J. Witter, Matthew H. Daniels, Angie R. Angeles, Phieng Siliphaivanh, David Sloman, Brendan O'Boyle, Danielle Falcone, Catherine White, Ron Ferguson, Wei Zhou, Kathryn Lipford, Umar Faruk Mansoor, Salem Fevrier, Xianhai Huang, Ravi Kurukulasuriya, Judson E. Richard, Shuyi Tang, Christopher Boyce, Joseph Kozlowski, Raman Kumar Bakshi, Ganesh Babu Karunakaran
  • NOVEL COMPOUNDS THAT ARE ERK INHIBITORS
    Publication number: 20150266895
    Abstract: Disclosed are the ERK inhibitors of formula (1): and the pharmaceutically acceptable salts thereof. Also disclosed are methods of treating cancer using the compounds of formula (1).
    Type: Application
    Filed: September 26, 2013
    Publication date: September 24, 2015
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Kevin J. Wilson, David J. Witter, Phieng Siliphaivanh, Kathryn Lipford, David Sloman, Danielle Falcone, Brendan O'Boyle, Umar Faruk Mansoor, Jongwon Lim, Joey L. Methot, Christopher Boyce, Lei Chen, Matthew H. Daniels, Salem Fevrier, Xianhai Huang, Ravi Kurukulasuriya, Ling Tong, Wei Zhou, Joseph Kozlowski, Milana M. Maletic, Bidhan A. Shinkre, Jayanth Thiruvellore Thatai, Raman Kumar Bakshi, Ganesh Babu Karunakaran
  • NOVEL COMPOUNDS THAT ARE ERK INHIBITORS
    Publication number: 20150258074
    Abstract: Disclosed are the ERK inhibitors of formula (1.0), having a pyrazolopyridine base structure, and the pharmaceutically acceptable salts thereof. Also disclosed are methods of treating cancer using the compounds of formula (1.0).
    Type: Application
    Filed: September 26, 2013
    Publication date: September 17, 2015
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: Kevin J. Wilson, David J. Witter, Matthew H. Daniels, Angie R. Angeles, Phieng Siliphaivanh, David Sloman, Brendan O'Boyle, Danielle Falcone, Catherine White, Ron Ferguson, Wei Zhou, Kathryn Lipford, Umar Faruk Mansoor, Salem Fevrier, Xianhai Huang, Ravi Kurukulasuriya, Judson E. Richard, Shuyi Tang, Christopher Boyce, Joseph Kozlowski, Raman Kumar Bakshi, Ganesh Babu Karunakaran
  • Compounds that are ERK inhibitors
    Patent number: 9023865
    Abstract: Disclosed are the ERK inhibitors of formula (1): and the pharmaceutically acceptable salts thereof. Also disclosed are methods of treating cancer using the compounds of formula (1).
    Type: Grant
    Filed: October 25, 2012
    Date of Patent: May 5, 2015
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Jongwon Lim, Elizabeth Helen Kelley, Joey L. Methot, Hua Zhou, Alessia Petrocchi, Umar Faruk Mansoor, Christian Fischer, Brendan O'Boyle, David Joseph Guerin, Corey E. Bienstock, Christopher W. Boyce, Matthew H. Daniels, Danielle Falcone, Ronald D. Ferguson, Salem Fevrier, Xianhai Huang, Kathryn Ann Lipford, David L. Sloman, Kevin Wilson, Wei Zhou, David Witter, Milana M. Maletic, Phieng Siliphaivanh